qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias Translocations of the MLL (Mixed Lineage Leukemia) gene are frequently found in human leukemias affecting both children and adults. Fusion of MLL to one of more than 60 genes results in generation of oncogenic proteins upregulating Hox genes, which are vital to blood cell development. Patients harboring fusion of the MLL gene suffer from aggressive leukemias and respond poorly to available therapies. All of the oncogenic fusion proteins have a preserved N-terminal fragment of MLL that has been identified to interact with menin. It has been recently discovered that association with menin is critical to the leukemogenic activity of the MLL fusion oncoproteins. Selective targeting of the menin-MLL interaction could provide an attractive therapeutic approach to develop novel drugs for MLL-related leukemias. Small molecules blocking the menin-MLL interaction should reverse the oncogenic potential of MLL fusion proteins. We have developed and optimized a fluorescence polarization-based assay for the identification of Menin-MLL inhibitors. The assay was run employing two different MLL-derived peptides. The present assay uses a 12 amino acid peptide labeled with fluorescein at its N-terminus. This peptide consists of the menin high affinity binding motif from MLL and is potently bound by menin. Another peptide with a mutated sequence, labeled with Texas Red, was used in parallel as a less stringent screen for inhibitors. The Menin protein, the MLL-wild type (w.t.) derived peptide (N-terminal 12 amino acids), the MLL-derived peptide labeled with Texas Red and the MLL-w.t. peptide labeled with Fluorescein were kindly supplied by laboratory of Dr. Jolanta Grembecka, University of Virginia. All protein and peptide solutions were stored in single use aliquots at -80C. The Eu3+ Cyrptate-conjugated mouse monoclonal antibody anti-6 Histidine  (Eu3+-AB) and  the Streptavidin-XL665 conjugate (XL665) were purchased from Cisbio International (Bedford, MA). All antibody and XL665 conjugate solution stocks were stored in single use aliquots at -20C. The Buffer components for all assays were purchased from Sigma-Aldrich (St. Louis, MO) and Invitrogen (Carlsbad, CA). FP Assay Reagents: 1. FP reaction buffer: 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 1mM DTT. Before use, 0.05% BSA is added. 2. Menin protein, MLL-w.t. labeled with fluorescein, MLL-mutant peptide labeled with texas red. Stored in singe use aliquots at -80C. 3. MLL-w.t. unlabeled peptide as positive control: 10 uM final in FP buffer. FP Assay Procedure: 1. Prepare Menin at 200 nM, MLL-w.t.-fluorescein at 25 nM, and MLL-mutant-texas red at 50 nM mixture in FP buffer. 2. Prepare Menin at 200 nM, MLL-w.t.-fluorescein at 25 nM, MLL-mutant-texas red at 50 nM, and 10 uM MLL-w.t. unlabeled mixture in FP buffer. 3. Prepare MLL-w.t.-fluorescein at 25 nM and MLL-mutant-texas red at 50 nM mixture in FP buffer. 3. Dispense 4 ul per well of reagent in step 1 in columns 2, 4 - 48 in a black 1536 well plate, dispense 4 ul per well of reagents from steps 2 and 3 in columns 1 and 3 respectively.  Incubate plate at ambient for 15 minutes. 4. Transfer 23 nl per well of compound to plate and incubate at ambient for 1 hr. 5. Read fluorescence polarization for each label using the PerkinElmer Envision. Envision protocol for fluorescein: FITC FP Dual Enh Mirror, Excitation filter 480, Emission filter (1) P-pol 535, Emission filter (2) S-pol 535 Envision protocol for texas red: FP Dual Enh Mirror, Excitation filter 555, Emission filter (1) P-pol 632, Emission filter (2) S-pol 632
bao:BAO_0001067 "2778" ; # "is primary assay of" -> "2778"
bao:BAO_0001067 "2781" ; # "is primary assay of" -> "2781"
bao:BAO_0001067 "2782" ; # "is primary assay of" -> "2782"
bao:BAO_0001067 "2783" ; # "is primary assay of" -> "2783"
bao:BAO_0001067 "504537" ; # "is primary assay of" -> "504537"
bao:BAO_0000812 "2076" ; # "has summary assay" -> "2076"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000223 ; # "has assay format" -> "protein complex format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BAO_0000399 bao:BAO_0000282 ; # "has transcription factor" -> "transcription factor"
bao:BA0_0090012 bao:BAO_0000292 ; # "has participant" -> "transferase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_00020101 ; # "is bioassay type of" -> "protein-protein interaction assay"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Menin/MLL" ; # "protein-protein" -> "Menin/MLL"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000003 ; # "has detection method" -> "fluorescence polarization"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification for inhibitors targeting the Menin-MLL interaction in MLL related leukemias" ; # "screening campaign name" -> "Identification for inhibitors targeting the Menin-MLL interaction in MLL related leukemias"
bao:BAO_0002853 "qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide" ; # "has assay title" -> "qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide"
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "1 hour" ; # "has incubation time value" -> "1 hour"
bao:BA0_0090012 "MLL-WT unlabeled peptide" ; # "has participant" -> "MLL-WT unlabeled peptide"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Jolanta Grembecka" ; # "material entity assay provider" -> "Jolanta Grembecka"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Tomasz Cierpicki" ; # "material entity assay provider" -> "Tomasz Cierpicki" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000694 ; # "has participant" -> "Tris" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 "Menin" ; # "has participant" -> "Menin"
bao:BA0_0090012 "Histone-lysine N-methyletransferase MLL" ; # "has participant" -> "Histone-lysine N-methyletransferase MLL"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q03164" ; # "uniprot ID" -> "Q03164"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "O00255" ; # "uniprot ID" -> "O00255"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0001026 ; # "has participant" -> "Texas red"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0002917 "555 nanometer" ; # "has excitation wavelength value" -> "555 nanometer"
bao:BAO_0002918 "632 nanometer" ; # "has emission wavelength value" -> "632 nanometer"
bao:BAO_0000208 bao:BAO_0000186 ; # "has endpoint" -> "AC50"
bao:BAO_0000337 bao:BAO_0000656 ; # "has percent response" -> "efficacy"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "3" ; # "PubChem TID" -> "3"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002787 "24" ; # "has concentration-point number" -> "24"
bao:BAO_0002845 "2" ; # "has repetition point-number" -> "2"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie" ; # "Annotated by" -> "kunie"
